Type 2 Diabetes Clinical Trial
— iADAPTOfficial title:
Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination
NCT number | NCT01493258 |
Other study ID # | NA_00040442 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2010 |
Verified date | May 2019 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this project the investigators seek to utilize our experience for developing a
comprehensive informatics framework for rapid adaptation and dissemination of Comparative
Effectiveness Research (CER) products tailored to different categories of health consumers
including difficult-to-reach patients. Based on our previous successful experience in
computer-assisted education, the investigators will refine the current CO-ED platform to
implement and test a novel system for individualized continuous patient education (iCOPE).
The iCOPE platform will be specifically designed to support rapid adaptation, customization,
and dissemination of the CER products to the difficult-to-reach populations. The iCOPE
platform will implement universal means for customized delivery of CER information in the
format of interactive self-paced educational modules, quick "question & answer" guides, and
interactive decision aids. In addition, the iCOPE platform will support the innovative
concept of continuous patient health education by providing patients with easy access to the
interactive CER updates via web, MP3 players and phone-based interactive voice response (IVR)
technology. Though iCOPE will be designed to support the whole spectrum of CER products, in
this project the investigators will focus on the Comparative Effectiveness Research Summary
Guide (CERSG) entitled "Pills for Type 2 Diabetes."
The following primary hypothesis will be tested in the RCT: Use of the iCOPE platform will be
associated with improvement in CERSG knowledge in elderly at 6 months after the intervention.
The investigators will also examine the impact of iCOPE on medication adherence
self-efficacy, diabetes medication satisfaction, HbA1c, and CERSG acceptance.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - have clinical diagnosis of Type 2 diabetes; - take oral diabetes medications; - be 65 years of age or older at the time of randomization; - plan to remain in the Maryland/DC area until the completion of the study follow-up; - understand English at the 5th grade level. Exclusion Criteria: - plan to leave Maryland/DC area before the completion of the study follow- up; - presence of significant cognitive impairment based on a Mini-Mental State Examination (MMSE) score =23 - do not speak English. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Brod M, Christensen T, Kongsø JH, Bushnell DM. Examining and interpreting responsiveness of the Diabetes Medication Satisfaction measure. J Med Econ. 2009;12(4):309-16. doi: 10.3111/13696990903337017. — View Citation
Finkelstein J, Lapshin O, Cha E. Feasibility of promoting smoking cessation among methadone users using multimedia computer-assisted education. J Med Internet Res. 2008 Nov 3;10(5):e33. doi: 10.2196/jmir.1089. — View Citation
Finkelstein J, Lapshin O, Wasserman E. Randomized study of different anti-stigma media. Patient Educ Couns. 2008 May;71(2):204-14. doi: 10.1016/j.pec.2008.01.002. Epub 2008 Mar 4. — View Citation
Finkelstein J, Lapshin O. Reducing depression stigma using a web-based program. Int J Med Inform. 2007 Oct;76(10):726-34. Epub 2006 Sep 20. — View Citation
Fitzgerald JT, Funnell MM, Hess GE, Barr PA, Anderson RM, Hiss RG, Davis WK. The reliability and validity of a brief diabetes knowledge test. Diabetes Care. 1998 May;21(5):706-10. — View Citation
Huang JP, Chen HH, Yeh ML. A comparison of diabetes learning with and without interactive multimedia to improve knowledge, control, and self-care among people with diabetes in Taiwan. Public Health Nurs. 2009 Jul-Aug;26(4):317-28. doi: 10.1111/j.1525-1446.2009.00786.x. — View Citation
Jimison H, Gorman P, Woods S, Nygren P, Walker M, Norris S, Hersh W. Barriers and drivers of health information technology use for the elderly, chronically ill, and underserved. Evid Rep Technol Assess (Full Rep). 2008 Nov;(175):1-1422. Review. — View Citation
Lapshin OV, Sharma K, Finkelstein J. Depression education for primary care patients using a web-based program. AMIA Annu Symp Proc. 2005:1017. — View Citation
Longo DR. Understanding health information, communication, and information seeking of patients and consumers: a comprehensive and integrated model. Health Expect. 2005 Sep;8(3):189-94. — View Citation
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008 May;10(5):348-54. — View Citation
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986 Jan;24(1):67-74. — View Citation
Neafsey PJ, Anderson E, Peabody S, Lin CA, Strickler Z, Vaughn K. Beta testing of a network-based health literacy program tailored for older adults with hypertension. Comput Inform Nurs. 2008 Nov-Dec;26(6):311-9. doi: 10.1097/01.NCN.0000336466.17811.e7. — View Citation
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487-97. Review. — View Citation
Tian Y, Robinson JD. Incidental health information use and media complementarity: a comparison of senior and non-senior cancer patients. Patient Educ Couns. 2008 Jun;71(3):340-4. doi: 10.1016/j.pec.2008.02.006. Epub 2008 Mar 26. — View Citation
Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988 Dec;44(4):1049-60. Erratum in: Biometrics 1989 Mar;45(1):347. — View Citation
* Note: There are 15 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in CERSG Knowledge Score from baseline to 24-hr and to 6-month follow up | CERSG Knowledge Score will be used to assess the overall patient knowledge of the information provided in the CERSG entitled "Pills for Type 2 Diabetes." The score will represent a percentage of correct answers to 30 true/false items designed in accordance with the content of the CERSG. | The Knowledge Test will be administered at the baseline, 24-hr after the introduction of the CERSG, and at the 6-month follow-up. | |
Secondary | Medication adherence self-efficacy | Medication adherence self-efficacy will measure self-efficacy of taking medications. | The medication adherence self-efficacy measure will be administered at the baseline, 24-hr after the introduction of the CERSG, and at the 6-month follow-up. | |
Secondary | Diabetes Medication Satisfaction | Diabetes Medication Satisfaction measure is a diabetes-specific measure, assessing medication treatment satisfaction in three domains: Efficacy, Burden, Symptoms (Side Effects). | Diabetes medication satisfaction measure will be administered at the baseline and at the 6-month follow-up. | |
Secondary | Glucosylated hemoglobin (HbA1c) | Glucosylated hemoglobin (HbA1c) will be obtained from Electronic Medical Record (Centricity) at Johns Hopkins Community Physicians (JHCP). | Glucosylated hemoglobin (HbA1c) values will be obtained closest to the date of the baseline evaluation and 6-month follow-up. | |
Secondary | CERSG Acceptance | CERSG acceptance will measure patient acceptance and comprehension of CERSG | The CERSG acceptance measure will be administered at the baseline, 24-hr after the introduction of the CERSG, and at the 6-month follow-up. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |